Local view for "http://purl.org/linkedpolitics/eu/plenary/2005-09-06-Speech-2-348"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2005-09-06"^^xsd:date2
dcterms:Is Part Of	lp_eu:Medicinal products for paediatric use2
dcterms:Language	"de"^^xsd:language2
lpv:document identification number	"en.20050906.36.2-348"2
lpv:hasSubsequent	lp_eu:2005-09-06-Speech-2-3492
lpv:speaker	lp:Hiltrud Breyer2
lpv:spokenAs	member; G/EFA (2004-07-20--2009-07-13)3 member; FEMM (2004-07-21--2007-01-14)3 member; ENVI (2004-07-21--2007-01-14)3 substitute; Delegation to the EU-Romania Joint Parliamentary Committee (2004-12-06--2006-12-31)3 member; Delegation for relations with Japan (2004-09-15--2007-03-13)3 substitute; JURI (2004-07-21--2007-01-14)3 unknown; Bündnis 90/Die Grünen (2004-07-20--2009-07-13)3
lpv:translated text	"Mr President, we welcome this regulation. The fact that over 50% of the medicinal products used in Europe to treat children are neither tested on children nor authorised for paediatric use is preposterous and no longer acceptable. Why has the pharmaceutical industry, which is, after all, always preaching personal responsibility, not seen fit in the past to conduct these very studies itself? This is an indictment of the pharmaceutical industry: it is out to make a killing, a huge profit. That is why I think it appropriate that we should be honest about, and make no bones about, the fact that this debate in this House is about how this regulation must not be allowed to become the means whereby the few help themselves to the profits they are interested in. We must also, then, seek to lay down very clear conditions. We are not just talking of a couple of million euros here, but of sums into the millions and billions. I agree with those Members who say that patents need to be protected for a shorter period of time. We have re-tabled an amendment to extend patent protection to just four months, and I should once more like to ask all my fellow Members to support this amendment. We need, however, to make the conditions even clearer. These medicinal products must have a therapeutic benefit. After all, it is senseless to knowingly allow children to be made guinea pigs in tests in the absence of any therapeutic benefit: this is unacceptable. The clear aim must be for rewards to be reserved exclusively for those whose clinical trials have been successful. Only if we really act together on this can we truly speak of a success. We should not, however, allow this to give rise to an industry wish list; the focus must be on the interests of the children."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph